BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
See today's BioWorld
Home
» Futility at the interim: Biogen, Eisai pull plug on aducanumab for Alzheimer's
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Futility at the interim: Biogen, Eisai pull plug on aducanumab for Alzheimer's
March 22, 2019
By
Brian Orelli
No Comments
Quarter after quarter, analysts have been pestering management on Biogen Inc.'s conference calls about whether there would be an interim analysis for the phase III program testing its Alzheimer's disease drug aducanumab.
BioWorld